Heart Lung Machine Market Size, Share & Trends Analysis Report By Product (Single Roller Pump Heart Lung Machine, Double Roller Pump Heart Lung Machine), By Applications (Acute Respiratory Failure Treatment, Lung Transplant Operation, Cardiac Surgery), By End Use, By Region, and Segment Forecasts - 2035

Heart Lung Machine Market Overview

heart lung machine market size was valued at USD 309.15 million in 2025 and is poised to grow from USD 319.35 million in 2026 to USD 352.02 million by 2035, growing at a CAGR of 3.3% during the forecast period (2026-2035).

The Heart Lung Machine Market in 2026 is evolving around digitally integrated cardiopulmonary bypass platforms, improved blood-management technologies, patient-specific perfusion strategies, safer pump control, continuous monitoring, and increasingly modular system architecture. Double Roller Pump Heart Lung Machine systems are estimated to account for approximately 63% of Product Type demand because cardiac centers frequently require multiple independently controllable blood-flow circuits for arterial perfusion, cardiotomy suction, venting, and cardioplegia support. Single Roller Pump Heart Lung Machine systems represent approximately 37% of demand and remain relevant where hospitals prioritize simpler layouts and lower equipment complexity. By Application, Cardiac Surgery dominates with approximately 72% market share, Acute Respiratory Failure Treatment represents around 17%, and Lung Transplant Operation accounts for approximately 11%. Modern perfusion platforms increasingly integrate pump modules, patient monitoring, electronic data capture, safety alarms, blood-gas information, and workflow software within 1 coordinated system. Next-generation heart-lung platforms have already supported more than 100,000 patients globally since commercial introduction of a major digital perfusion architecture in 2023, demonstrating a rapid hospital upgrade cycle toward data-assisted extracorporeal circulation.

The United States remains one of the largest Heart Lung Machine Markets because high cardiac-surgery volumes, advanced hospital infrastructure, specialist perfusion teams, cardiovascular disease prevalence, transplantation programs, and frequent replacement of aging capital equipment sustain demand. North America is estimated to account for approximately 41% of global market activity in 2026. Double Roller Pump Heart Lung Machine configurations represent around 65% of regional Product Type demand, while Single Roller Pump Heart Lung Machine systems account for approximately 35%. Cardiac Surgery contributes nearly 74% of regional Application activity, Acute Respiratory Failure Treatment represents approximately 16%, and Lung Transplant Operation contributes around 10%. Hospitals increasingly prefer platforms that consolidate at least 4 functions including blood pumping, oxygenation monitoring, temperature management, and electronic perfusion documentation. The U.S. also supports a strong replacement market because heart-lung machines typically operate for several years but require continuous preventive maintenance and periodic modernization. New-generation systems are increasingly purchased alongside oxygenators, reservoirs, tubing sets, monitoring modules, and software to create a standardized perfusion environment rather than functioning as isolated pumps.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Double Roller Pump Heart Lung Machine systems are estimated to hold approximately 63% market share because complex perfusion procedures frequently require multiple independently managed blood-flow circuits and redundancy.
• Leading Application: Cardiac Surgery is estimated to account for approximately 72% of demand as cardiopulmonary bypass remains essential during coronary, valve, congenital, and other open-heart procedures.
• Leading Region: North America is estimated to hold approximately 41% market share, supported by advanced cardiac centers, high procedure volumes, established perfusion teams, and frequent equipment replacement.
• Fastest Growing Region: Asia-Pacific is projected to expand at approximately 5.8% annually as cardiac-surgery capacity, hospital investment, insurance coverage, and specialist perfusion infrastructure continue increasing.
• Technology Trend: Next-generation digital perfusion platforms have supported more than 100,000 patients globally since 2023, demonstrating rapid adoption of integrated monitoring and patient-tailored cardiopulmonary bypass.
• Market Driver: China alone was projected to perform approximately 208,500 extracorporeal circulation procedures in 2025, highlighting the expanding surgical base supporting heart-lung machine installations.
• Competitive Landscape: The 6 supplied companies collectively represent an estimated 68% of competitive market participation, reflecting strong concentration around established cardiovascular equipment manufacturers.
• Future Outlook: Approximately 80% of new placements for one leading next-generation heart-lung platform are targeted to transition to the latest digital architecture, reinforcing the global equipment replacement cycle.

Latest Trends

Integrated digital perfusion is the most important trend shaping the Heart Lung Machine Market in 2026. Traditional systems required perfusionists to interpret information from multiple independent devices, while newer architectures increasingly place pump operation, physiologic monitoring, alarms, flow measurements, and electronic documentation within a unified interface. One next-generation perfusion platform introduced in 2023 has already supported more than 100,000 patients worldwide, showing that hospitals are actively replacing legacy systems rather than waiting for complete fleet obsolescence. Digital platforms allow the perfusion team to track several operating variables simultaneously, including arterial flow, venous parameters, temperature, pressure, oxygenation, and patient-specific targets. Modern systems can use 4 or more pump modules depending on procedure complexity, enabling cardiac centers to configure equipment for adult, pediatric, transplantation, and specialist cardiothoracic procedures. Patient-tailored perfusion is becoming particularly important because clinicians increasingly adjust flow and oxygen-delivery strategies according to body size, metabolic demand, hematocrit, and procedural requirements rather than relying on standardized settings.

The second major trend is expansion of cardiopulmonary bypass capability across emerging healthcare systems. China has approximately 330 million people affected by cardiovascular disease and more than 700 hospitals capable of performing cardiac surgery, creating a substantial installed-base opportunity. Around 185,000 adult and approximately 23,500 pediatric extracorporeal circulation procedures were projected in China during 2025, representing more than 208,000 procedures requiring specialized extracorporeal technology. Manufacturers are responding by expanding regulatory approvals, local training, technical service networks, and consumable availability. Asia-Pacific therefore represents the fastest-growing regional market despite North America's larger installed base. Hospitals are also demanding improved oxygenators, integrated arterial filtration, lower priming volumes, continuous blood-gas monitoring, and better biocompatibility. These developments are reducing the distinction between the heart-lung machine and the broader perfusion ecosystem because equipment procurement increasingly includes hardware, oxygenation systems, monitoring technology, software, disposables, and long-term service agreements.

Market Dynamics

Driver

""Rising cardiac procedure volumes are sustaining long-term demand for advanced perfusion systems.""

The strongest driver of the Heart Lung Machine Market is the continuing burden of cardiovascular disease and the large number of patients requiring open-heart intervention. Cardiac Surgery accounts for approximately 72% of Application demand because cardiopulmonary bypass is routinely used when surgeons require a motionless and bloodless operative field. During bypass, the machine temporarily assumes 2 essential physiological functions by maintaining systemic blood circulation and supporting gas exchange through an oxygenator. Hospitals performing coronary artery bypass, valve procedures, congenital repair, aortic surgery, and complex combined operations therefore require dependable heart-lung equipment and trained perfusion personnel. Global demand is further supported by aging populations, because cardiovascular procedure utilization generally rises materially after age 60.

Expansion of cardiac-surgery capacity in emerging markets provides another major driver. More than 700 hospitals in China can perform cardiac surgery, while approximately 208,500 adult and pediatric extracorporeal circulation procedures were projected there during 2025. India, Southeast Asia, Latin America, and the Middle East are also expanding tertiary-care hospitals capable of providing advanced cardiovascular treatment. Each newly established cardiac center may require 1-3 heart-lung machines depending on operating-room volume and redundancy policies. Large hospitals operating several cardiac theaters can maintain substantially larger installed fleets because emergency backup capacity is critical during life-support procedures.

Restraint

""High capital requirements and specialist staffing limit adoption across smaller hospitals.""

The main restraint is the cost and operational complexity associated with establishing a cardiopulmonary bypass program. A heart-lung machine cannot be evaluated only as a stand-alone piece of equipment because hospitals also need oxygenators, reservoirs, tubing circuits, temperature-control systems, blood-monitoring technology, disposables, maintenance contracts, and trained perfusionists. A functional cardiac operating room may therefore involve more than 10 coordinated equipment and consumable categories. Smaller hospitals with limited cardiac volume can find this infrastructure difficult to justify, concentrating demand among tertiary hospitals and specialist cardiovascular centers.

Perfusion staffing is another limiting factor. The machine requires continuous expert supervision because arterial flow, pressure, oxygenation, temperature, anticoagulation, and fluid balance can change rapidly during surgery. Even a short interruption in circulation can create serious clinical risk. Hospitals therefore need trained teams rather than relying solely on equipment automation. Newer systems provide extensive alarms and digital assistance, but they do not remove the need for skilled clinical judgment. Asia-Pacific is growing at approximately 5.8% annually, yet expansion can be slower in locations where perfusion-training capacity does not keep pace with hospital construction.

Opportunity

""Digital replacement cycles create substantial opportunities for next-generation perfusion platforms.""

The most significant opportunity is replacement of legacy heart-lung machines with integrated digital systems. One leading manufacturer reported that approximately 55% of its heart-lung machine placements during 2025 were represented by its newer perfusion architecture, illustrating that the upgrade cycle is already underway. Its longer-term target anticipates approximately 80% of new placements transitioning to the latest platform. This replacement dynamic is important because hospitals can improve workflow without increasing procedure volume. A mature cardiac center may replace 2 or more older machines while simultaneously standardizing monitoring, data capture, and consumables.

Asia-Pacific creates another major opportunity because surgical infrastructure is expanding from a comparatively lower installed base. China's approximately 208,500 extracorporeal circulation procedures in 2025 illustrate the scale that can develop when treatment access broadens. India is also expected to expand faster than mature Western markets, with contemporary forecasts placing growth around 7.5% across the broader heart-lung equipment category. Suppliers that combine equipment installation, staff training, service support, and local consumable availability can capture more opportunities than companies selling hardware alone. Emerging-market procurement increasingly values total system uptime because a malfunctioning machine can disrupt an entire cardiac-surgery schedule.

Challenge

""Maintaining uninterrupted safety across complex extracorporeal circuits remains the core technical challenge.""

The principal challenge is maintaining reliable circulation and gas exchange throughout every stage of cardiopulmonary bypass. A modern perfusion circuit can include more than 8 functional elements such as arterial pumps, venous reservoirs, oxygenators, filters, cardioplegia systems, heat exchangers, pressure sensors, and blood-monitoring modules. Failure or incorrect configuration of any critical component can affect patient safety. Manufacturers therefore incorporate multiple alarms, backup pumps, battery support, occlusion controls, pressure monitoring, and emergency manual operation. Double Roller Pump Heart Lung Machine configurations account for approximately 63% of market demand partly because multiple pump channels provide the flexibility needed for complex procedures.

Another challenge is data overload. Digital platforms can display dozens of perfusion and patient variables simultaneously, but additional information only improves outcomes when clinicians can interpret it efficiently. Interface design is therefore becoming as important as mechanical performance. Alarms must identify clinically significant changes without generating excessive false notifications. Hospitals also need interoperability between perfusion systems and electronic patient records. Through 2035, market competition will increasingly center on at least 9 parameters including pump precision, monitoring integration, alarm management, cybersecurity, software usability, oxygenator compatibility, service reliability, backup capability, and clinical workflow efficiency.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Single Roller Pump Heart Lung Machine: Single Roller Pump Heart Lung Machine systems are estimated to account for approximately 37% market share. These configurations provide controlled blood propulsion through compression of flexible tubing and can support cardiac procedures where hospitals prefer simpler system architecture. Single-pump designs can be appropriate for lower-volume operating environments, training programs, and selected procedures requiring fewer simultaneously controlled extracorporeal circuits. Their comparatively straightforward mechanical layout can also reduce some service and configuration requirements. Nevertheless, growing procedural complexity is gradually shifting demand toward multi-pump systems capable of controlling several blood-management functions independently.

Double Roller Pump Heart Lung Machine: Double Roller Pump Heart Lung Machine systems lead with approximately 63% market share because modern cardiac surgery frequently requires multiple independently controlled perfusion functions. Separate pumps can support arterial circulation, cardioplegia, suction, venting, or other blood-management tasks depending on system architecture. Larger cardiac centers may configure 4 or more pump modules around the primary perfusion platform. Double-pump and modular configurations therefore provide the flexibility required for high-volume adult, pediatric, transplantation, and complex cardiovascular procedures. Their dominance is expected to continue through 2035 as hospitals increasingly adopt configurable digital perfusion workstations.

By Applications

Acute Respiratory Failure Treatment: Acute Respiratory Failure Treatment accounts for approximately 17% market share. Extracorporeal blood-circulation technologies can support patients when normal pulmonary gas exchange is inadequate, although the exact system architecture differs from conventional operating-room cardiopulmonary bypass. Acute-support requirements increased significantly during periods of severe respiratory disease, accelerating clinical familiarity with extracorporeal technologies. Modern cardiac companies increasingly maintain portfolios covering both cardiopulmonary bypass and longer-duration extracorporeal support, creating technology overlap in pumps, oxygenators, tubing, monitoring, and blood-management expertise.

Lung Transplant Operation: Lung Transplant Operation represents approximately 11% market share. Heart-lung equipment can support circulation and oxygenation during technically demanding transplantation procedures when a patient's native cardiopulmonary function is insufficient. Lung transplantation remains much lower in volume than Cardiac Surgery, but each procedure requires highly specialized equipment and multidisciplinary teams. Major transplant centers often maintain dedicated extracorporeal capability and backup systems because procedure timing can be unpredictable and donor-organ availability may require surgery at any hour.

Cardiac Surgery: Cardiac Surgery dominates with approximately 72% market share because conventional cardiopulmonary bypass remains central to many open-heart operations. Coronary bypass, valve repair or replacement, congenital correction, aortic surgery, and combined procedures create substantial demand for pumps, oxygenators, monitoring systems, and disposable circuits. China alone projected approximately 208,500 extracorporeal circulation procedures during 2025, demonstrating the scale available within a single major national market. Increased cardiovascular disease prevalence and greater access to surgery will continue supporting this Application through 2035.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to lead the Heart Lung Machine Market with approximately 41% global share in 2026. Double Roller Pump Heart Lung Machine systems account for around 65% of regional Product Type demand, while Single Roller Pump Heart Lung Machine systems contribute approximately 35%. Cardiac Surgery represents approximately 74% of Applications, Acute Respiratory Failure Treatment accounts for 16%, and Lung Transplant Operation contributes around 10%. Medtronic provides strong supplied-company representation from the United States, while the region also contains a dense network of academic and specialized cardiovascular hospitals.

The region benefits from high cardiovascular procedure volumes, advanced reimbursement systems, transplant programs, perfusion expertise, and a large installed equipment base requiring replacement. North America's global market share is estimated at around 41%, while the United States accounts for the majority of regional consumption. New-generation platform adoption is increasing as hospitals replace systems that may have operated for 8-12 years. Digital documentation, integrated monitoring, automated safety functions, and service contracts increasingly influence procurement alongside pump reliability.

Europe

Europe is estimated to account for approximately 29% of global Heart Lung Machine Market demand. Double Roller Pump Heart Lung Machine configurations represent around 64% of Product Type activity, while Single Roller Pump Heart Lung Machine systems account for approximately 36%. Cardiac Surgery contributes around 73% of regional Applications, Acute Respiratory Failure Treatment represents 16%, and Lung Transplant Operation accounts for approximately 11%. LivaNova and Getinge provide major supplied-company representation from the United Kingdom and Sweden.

Europe has a mature cardiac-surgery network and is an important center for perfusion-system development. Long-term service agreements remain important because hospitals need uninterrupted availability of high-value capital equipment. During 2025-2026, European healthcare organizations continued placing maintenance and support agreements covering heart-lung equipment and associated autotransfusion systems. New digital platforms are increasingly replacing older generations as centers seek patient-tailored perfusion and more structured data capture. Europe is expected to expand at approximately 3.0-4.0% annually through 2035.

Asia-Pacific

Asia-Pacific is estimated to account for approximately 24% of global Heart Lung Machine Market demand and is projected to be the fastest-growing region at approximately 5.8% annually. Double Roller Pump Heart Lung Machine systems represent around 61% of regional Product Type demand, while Single Roller Pump Heart Lung Machine configurations contribute approximately 39%. Cardiac Surgery accounts for around 70% of Applications, Acute Respiratory Failure Treatment contributes 19%, and Lung Transplant Operation represents approximately 11%. Terumo CV Group and Tianjin Medical provide supplied-company representation from Japan and China.

China represents one of the most significant regional opportunities, with approximately 330 million people affected by cardiovascular disease and more than 700 hospitals capable of cardiac surgery. About 185,000 adult and 23,500 pediatric extracorporeal circulation procedures were projected there during 2025. A next-generation perfusion platform also entered commercial launch in China during August 2025 following regulatory approval, accelerating the shift toward digital perfusion. India and Southeast Asia provide additional growth as tertiary cardiac centers expand and private healthcare investment increases.

Middle East & Africa

Middle East & Africa is estimated to account for approximately 2% of global Heart Lung Machine Market demand. Double Roller Pump Heart Lung Machine systems represent around 60% of regional Product Type activity, while Single Roller Pump Heart Lung Machine systems contribute approximately 40%. Cardiac Surgery accounts for approximately 69% of Applications, Acute Respiratory Failure Treatment represents around 20%, and Lung Transplant Operation contributes approximately 11%.

Saudi Arabia, the United Arab Emirates, South Africa, Egypt, and selected Gulf healthcare hubs are expanding advanced cardiovascular services. Large specialist hospitals increasingly procure equipment comparable with European and North American cardiac centers, while many African markets remain constrained by limited perfusion staffing and infrastructure. Establishing 1 new cardiac-surgery program requires not only a heart-lung machine but multiple complementary devices and a trained multidisciplinary team. Regional demand is expected to expand approximately 4.0-5.0% annually through 2035.

List of Top Heart Lung Machine Companies

• LivaNova (Sorin) (U.K.)
• Getinge (Maquet) (Sweden)
• Medtronic (U.S.)
• Terumo CV Group (Japan)
• Braile Biomedica (Brazil)
• Tianjin Medical (China)

Top 2 Companies Market Share

Medtronic: Medtronic is estimated to hold approximately 18-21% competitive market share among major Heart Lung Machine participants, supported by a broad cardiac-surgery and extracorporeal support portfolio. The company expanded its extracorporeal technology offering during 2024 with a configurable platform designed to support both bedside treatment and intra-hospital transport. Its installed relationships across thousands of cardiovascular centers provide strong opportunities for pumps, oxygenation technology, monitoring equipment, and service support.

LivaNova (Sorin): LivaNova is estimated to hold approximately 17-20% competitive market share, supported by its established heart-lung machine heritage and rapidly expanding next-generation perfusion platform. The newer system surpassed 100,000 supported patients globally after its 2023 launch, while approximately 55% of the company's heart-lung machine placements during 2025 involved the next-generation architecture. The company's cardiopulmonary business grew by approximately 14% on a constant-currency basis during the first quarter of 2026, reflecting continued equipment and consumable demand.

Investment Analysis

Investment in the Heart Lung Machine Market increasingly targets digital perfusion platforms, integrated monitoring, oxygenator capacity, blood-management technology, software, service infrastructure, and manufacturing expansion. The largest suppliers are investing simultaneously in capital equipment and consumables because every new machine placement creates recurring demand for procedure-specific disposable products. One major cardiopulmonary manufacturer recorded approximately 14% constant-currency growth during the first quarter of 2026, driven by new perfusion-system placements and strong consumables demand. Its full-year 2025 cardiopulmonary operations had also increased by more than 13% on a constant-currency basis, demonstrating strong investment momentum despite the broader market's more moderate long-term equipment CAGR.

Manufacturing capacity is another important investment area because demand for oxygenators and associated cardiopulmonary consumables has periodically exceeded available supply. Manufacturers are therefore increasing output while diversifying component sourcing. Digital replacement cycles create additional opportunities because leading suppliers expect the newest platform generation to account for a majority of future installations. Through 2035, investment will increasingly concentrate across at least 9 areas: pump technology, oxygenators, sensing, patient monitoring, electronic documentation, cybersecurity, service networks, consumable manufacturing, and clinical training. Companies able to combine these functions can capture both initial machine placements and recurring procedure-related demand.

New Product Development

New Product Development in the Heart Lung Machine Market is centered on integrated digital perfusion, improved blood-flow control, continuous sensing, lower-prime oxygenation systems, patient-specific decision support, and simplified user interfaces. Next-generation platforms increasingly combine the heart-lung machine with multiple sensing technologies and an integrated patient monitor. More than 100,000 patients have already been supported by one major new-generation system since its 2023 launch, demonstrating relatively rapid clinical acceptance. New platforms can coordinate several pump modules while recording perfusion information electronically, reducing manual documentation. Manufacturers are also improving alarm architecture so clinicians can prioritize significant changes rather than responding to multiple independent device alerts.

Product development is simultaneously expanding around oxygenation and extracorporeal support. Modern oxygenators integrate arterial filtration and are designed to reduce circuit complexity, while continuous blood-gas monitoring gives perfusion teams more immediate information than periodic laboratory measurements alone. Manufacturers are also developing systems that bridge conventional cardiac-surgery support and longer-duration extracorporeal applications. During 2024, a configurable extracorporeal platform was introduced to support bedside care and movement within hospitals. Through 2035, new products will increasingly compete across at least 10 criteria: pump precision, oxygen-transfer efficiency, monitoring integration, priming volume, hemocompatibility, data capture, user-interface design, portability, redundancy, and connectivity.

Five Recent Developments

• May 2026: Next-generation perfusion-system placements continued rising, with one major cardiopulmonary business reporting approximately 14% constant-currency quarterly growth alongside strong consumable demand and equipment adoption.
• February 2026: One leading manufacturer reported that approximately 55% of its 2025 heart-lung machine placements used its latest perfusion architecture, demonstrating rapid transition away from legacy systems.
• December 2025: European healthcare procurement included extended maintenance agreements covering heart-lung machines and autotransfusion equipment for approximately 12 months, highlighting growing demand for lifecycle service support.
• August 2025: A next-generation digital perfusion platform launched commercially in China after regulatory approval, having already supported more than 100,000 patients worldwide since its 2023 introduction.
• September 2024: A configurable extracorporeal support platform was introduced to bridge bedside care and intra-hospital transport, extending cardiopulmonary technology toward more flexible acute heart and lung support.

Report Coverage

The Heart Lung Machine Market report covers the 2026-2035 forecast period using the stated 2025 baseline and evaluates the supplied Product Types of Single Roller Pump Heart Lung Machine and Double Roller Pump Heart Lung Machine. Estimated Product Type shares are approximately 37% and 63%, respectively. Application coverage includes Acute Respiratory Failure Treatment at approximately 17%, Lung Transplant Operation at 11%, and Cardiac Surgery at 72%. The analysis evaluates cardiopulmonary bypass, roller pumps, modular pump architecture, oxygenation, reservoirs, cardioplegia, blood-flow monitoring, pressure measurement, temperature management, continuous blood-gas monitoring, patient-tailored perfusion, electronic documentation, digital alarm management, service agreements, equipment replacement, extracorporeal support, and specialist perfusion training. A leading next-generation digital perfusion platform has supported more than 100,000 patients globally since 2023, illustrating the speed of technology transition.

Regional coverage includes North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, with estimated market shares of approximately 41%, 29%, 24%, 4%, and 2%, respectively. Competitive coverage includes all 6 supplied companies: LivaNova (Sorin), Getinge (Maquet), Medtronic, Terumo CV Group, Braile Biomedica, and Tianjin Medical. The report evaluates how approximately 208,500 annual extracorporeal circulation procedures in China, more than 700 cardiac-surgery hospitals in that market, increasing digital-platform penetration, stronger consumable manufacturing, advanced oxygenators, integrated monitoring, and multi-year replacement cycles will influence the Heart Lung Machine Market through 2035. Double Roller Pump Heart Lung Machine systems remain the leading Product Type with approximately 63% share, while Cardiac Surgery remains the dominant Application with approximately 72% of market demand.